Literature DB >> 31907178

Hydroxylamine and Carboxymethoxylamine Can Inhibit Toxoplasma gondii Growth through an Aspartate Aminotransferase-Independent Pathway.

Jixu Li1, Huanping Guo1, Eloiza May Galon1, Yang Gao1, Seung-Hun Lee1,2, Mingming Liu1, Yongchang Li1, Shengwei Ji1, Honglin Jia3, Xuenan Xuan4.   

Abstract

Toxoplasma gondii is an obligate intracellular protozoan parasite and a successful parasitic pathogen in diverse organisms and host cell types. Hydroxylamine (HYD) and carboxymethoxylamine (CAR) have been reported as inhibitors of aspartate aminotransferases (AATs) and interfere with the proliferation in Plasmodium falciparum Therefore, AATs are suggested as drug targets against Plasmodium The T. gondii genome encodes only one predicted AAT in both T. gondii type I strain RH and type II strain PLK. However, the effects of HYD and CAR, as well as their relationship with AAT, on T. gondii remain unclear. In this study, we found that HYD and CAR impaired the lytic cycle of T. gondii in vitro, including the inhibition of invasion or reinvasion, intracellular replication, and egress. Importantly, HYD and CAR could control acute toxoplasmosis in vivo Further studies showed that HYD and CAR could inhibit the transamination activity of rTgAAT in vitro However, our results confirmed that deficiency of AAT in both RH and PLK did not reduce the virulence in mice, although the growth ability of the parasites was affected in vitro HYD and CAR could still inhibit the growth of AAT-deficient parasites. These findings indicated that HYD and CAR inhibition of T. gondii growth and control of toxoplasmosis can occur in an AAT-independent pathway. Overall, further studies focusing on the elucidation of the mechanism of inhibition are warranted. Our study hints at new substrates of HYD and CAR as potential drug targets to inhibit T. gondii growth.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Toxoplasma gondii; aspartate aminotransferase; carboxymethoxylamine; hydroxylamine; toxoplasmosis

Year:  2020        PMID: 31907178      PMCID: PMC7038254          DOI: 10.1128/AAC.01889-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Purification, crystallization and preliminary X-ray analysis of the aspartate aminotransferase of Plasmodium falciparum.

Authors:  Rishabh Jain; Rositsa Jordanova; Ingrid B Müller; Carsten Wrenger; Matthew R Groves
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-03-31

2.  Construction of Toxoplasma gondii bradyzoite expressing the green fluorescent protein.

Authors:  Yoshifumi Nishikawa; Houshuang Zhang; Hany M Ibrahim; Fumiki Ui; Ayako Ogiso; Xuenan Xuan
Journal:  Parasitol Int       Date:  2007-10-18       Impact factor: 2.230

3.  Distinct signalling pathways control Toxoplasma egress and host-cell invasion.

Authors:  Sebastian Lourido; Keliang Tang; L David Sibley
Journal:  EMBO J       Date:  2012-11-13       Impact factor: 11.598

4.  Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.

Authors:  Suzanne Scheele; Jennifer A Geiger; Amy E DeRocher; Ryan Choi; Tess R Smith; Matthew A Hulverson; Rama Subba Rao Vidadala; Lynn K Barrett; Dustin J Maly; Ethan A Merritt; Kayode K Ojo; Wesley C Van Voorhis; Marilyn Parsons
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

5.  Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis.

Authors:  Arpron Leesombun; Masatomi Iijima; Kousuke Umeda; Daisuke Kondoh; Baldorj Pagmadulam; Ahmed M Abdou; Yutaka Suzuki; Shun-Ichi Ohba; Kunio Isshiki; Tomoyuki Kimura; Yumiko Kubota; Ryuichi Sawa; Coh-Ichi Nihei; Yoshifumi Nishikawa
Journal:  J Infect Dis       Date:  2020-02-18       Impact factor: 5.226

6.  In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.

Authors:  M G Reynolds; J Oh; D S Roos
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease.

Authors:  D K Howe; L D Sibley
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

Review 8.  Population structure of Toxoplasma gondii: clonal expansion driven by infrequent recombination and selective sweeps.

Authors:  L David Sibley; James W Ajioka
Journal:  Annu Rev Microbiol       Date:  2008       Impact factor: 15.500

9.  A Toxoplasma gondii Gluconeogenic Enzyme Contributes to Robust Central Carbon Metabolism and Is Essential for Replication and Virulence.

Authors:  Martin Blume; Richard Nitzsche; Ulrich Sternberg; Motti Gerlic; Seth L Masters; Nishith Gupta; Malcolm J McConville
Journal:  Cell Host Microbe       Date:  2015-08-12       Impact factor: 21.023

Review 10.  Apicomplexan Energy Metabolism: Carbon Source Promiscuity and the Quiescence Hyperbole.

Authors:  Damien Jacot; Ross F Waller; Dominique Soldati-Favre; Dougal A MacPherson; James I MacRae
Journal:  Trends Parasitol       Date:  2015-10-17
View more
  3 in total

Review 1.  Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.

Authors:  Karim Zuhra; Fiona Augsburger; Tomas Majtan; Csaba Szabo
Journal:  Biomolecules       Date:  2020-04-30

2.  Toxoplasma gondii and Neospora caninum Infections in Stray Cats and Dogs in the Qinghai-Tibetan Plateau Area, China.

Authors:  Jinfang Yang; Jingkai Ai; Tongsheng Qi; Xiaomin Ni; Zichun Xu; Liangting Guo; Yali Sun; Ying Li; Ming Kang; Jixu Li
Journal:  Animals (Basel)       Date:  2022-05-28       Impact factor: 3.231

3.  Genetic Disruption of Toxoplasma gondii peroxiredoxin (TgPrx) 1 and 3 Reveals the Essential Role of TgPrx3 in Protecting Mice from Fatal Consequences of Toxoplasmosis.

Authors:  Ragab M Fereig; Yoshifumi Nishikawa
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.